Mimicking the Kidney: A Key Role in Organ-on-Chip Development

Pharmaceutical drug screening and research into diseases call for significant improvement in the effectiveness of current in vitro models. Better models would reduce the likelihood of costly failures at later drug development stages, while limiting or possibly even avoiding the use of animal models....

Full description

Bibliographic Details
Main Authors: Roberto Paoli, Josep Samitier
Format: Article
Language:English
Published: MDPI AG 2016-07-01
Series:Micromachines
Subjects:
Online Access:http://www.mdpi.com/2072-666X/7/7/126
id doaj-11c79740d0634407b9d5906a8af0301b
record_format Article
spelling doaj-11c79740d0634407b9d5906a8af0301b2020-11-24T23:46:54ZengMDPI AGMicromachines2072-666X2016-07-017712610.3390/mi7070126mi7070126Mimicking the Kidney: A Key Role in Organ-on-Chip DevelopmentRoberto Paoli0Josep Samitier1Nanobioengineering Laboratory, Institute for Bioengineering of Catalonia (IBEC), Barcelona 08028, SpainNanobioengineering Laboratory, Institute for Bioengineering of Catalonia (IBEC), Barcelona 08028, SpainPharmaceutical drug screening and research into diseases call for significant improvement in the effectiveness of current in vitro models. Better models would reduce the likelihood of costly failures at later drug development stages, while limiting or possibly even avoiding the use of animal models. In this regard, promising advances have recently been made by the so-called “organ-on-chip” (OOC) technology. By combining cell culture with microfluidics, biomedical researchers have started to develop microengineered models of the functional units of human organs. With the capacity to mimic physiological microenvironments and vascular perfusion, OOC devices allow the reproduction of tissue- and organ-level functions. When considering drug testing, nephrotoxicity is a major cause of attrition during pre-clinical, clinical, and post-approval stages. Renal toxicity accounts for 19% of total dropouts during phase III drug evaluation—more than half the drugs abandoned because of safety concerns. Mimicking the functional unit of the kidney, namely the nephron, is therefore a crucial objective. Here we provide an extensive review of the studies focused on the development of a nephron-on-chip device.http://www.mdpi.com/2072-666X/7/7/126organ-on-chipkidneynephron-on-chipdisease modeldrug discovery
collection DOAJ
language English
format Article
sources DOAJ
author Roberto Paoli
Josep Samitier
spellingShingle Roberto Paoli
Josep Samitier
Mimicking the Kidney: A Key Role in Organ-on-Chip Development
Micromachines
organ-on-chip
kidney
nephron-on-chip
disease model
drug discovery
author_facet Roberto Paoli
Josep Samitier
author_sort Roberto Paoli
title Mimicking the Kidney: A Key Role in Organ-on-Chip Development
title_short Mimicking the Kidney: A Key Role in Organ-on-Chip Development
title_full Mimicking the Kidney: A Key Role in Organ-on-Chip Development
title_fullStr Mimicking the Kidney: A Key Role in Organ-on-Chip Development
title_full_unstemmed Mimicking the Kidney: A Key Role in Organ-on-Chip Development
title_sort mimicking the kidney: a key role in organ-on-chip development
publisher MDPI AG
series Micromachines
issn 2072-666X
publishDate 2016-07-01
description Pharmaceutical drug screening and research into diseases call for significant improvement in the effectiveness of current in vitro models. Better models would reduce the likelihood of costly failures at later drug development stages, while limiting or possibly even avoiding the use of animal models. In this regard, promising advances have recently been made by the so-called “organ-on-chip” (OOC) technology. By combining cell culture with microfluidics, biomedical researchers have started to develop microengineered models of the functional units of human organs. With the capacity to mimic physiological microenvironments and vascular perfusion, OOC devices allow the reproduction of tissue- and organ-level functions. When considering drug testing, nephrotoxicity is a major cause of attrition during pre-clinical, clinical, and post-approval stages. Renal toxicity accounts for 19% of total dropouts during phase III drug evaluation—more than half the drugs abandoned because of safety concerns. Mimicking the functional unit of the kidney, namely the nephron, is therefore a crucial objective. Here we provide an extensive review of the studies focused on the development of a nephron-on-chip device.
topic organ-on-chip
kidney
nephron-on-chip
disease model
drug discovery
url http://www.mdpi.com/2072-666X/7/7/126
work_keys_str_mv AT robertopaoli mimickingthekidneyakeyroleinorganonchipdevelopment
AT josepsamitier mimickingthekidneyakeyroleinorganonchipdevelopment
_version_ 1725491746443362304